Furthermore, loss of PTPN2 in patients with triple-negative breast cancer was associated with poor response to tamoxifen (40, 41) demonstrating the relevance of this phosphatase to the response of human cancer to chemotherapy in addition to immunotherapy. This evidence concerns the gene PTPN2 and triple-negative breast carcinoma.